ES2103468T3 - Tratamiento de la inflamacion intestinal. - Google Patents

Tratamiento de la inflamacion intestinal.

Info

Publication number
ES2103468T3
ES2103468T3 ES93904830T ES93904830T ES2103468T3 ES 2103468 T3 ES2103468 T3 ES 2103468T3 ES 93904830 T ES93904830 T ES 93904830T ES 93904830 T ES93904830 T ES 93904830T ES 2103468 T3 ES2103468 T3 ES 2103468T3
Authority
ES
Spain
Prior art keywords
treatment
intestinal inflammation
tissus
ibd
endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93904830T
Other languages
English (en)
Inventor
Roy R Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25268692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2103468(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ES2103468T3 publication Critical patent/ES2103468T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE DESCRIBE UN METODO PARA EL TRATAMIENTO DE (IBD) (INFLAMMATORY BOWEL DISEASE O). EL METODO COMPRENDE LA ADMINISTRACION DE UN ANTICUERPO, POLIPEPTIDO U OTRA MOLECULA COMPRENDIENDO VLA-4, UNA MOLECULA SUPERFICIAL EXPRESADA EN LA MAYOR CLASE DE TIPOS DE GLOBULOS SANGUINEOS BLANCOS E IMPLICADA EN LA ADHERENCIA DE LEUCOCITOS AL ENDOTELIO Y OTROS TEJIDOS EN EL TUBO DIGESTIVO.
ES93904830T 1992-02-12 1993-02-02 Tratamiento de la inflamacion intestinal. Expired - Lifetime ES2103468T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83513992A 1992-02-12 1992-02-12

Publications (1)

Publication Number Publication Date
ES2103468T3 true ES2103468T3 (es) 1997-09-16

Family

ID=25268692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93904830T Expired - Lifetime ES2103468T3 (es) 1992-02-12 1993-02-02 Tratamiento de la inflamacion intestinal.

Country Status (10)

Country Link
EP (1) EP0625912B1 (es)
JP (3) JPH07506566A (es)
AT (1) ATE151642T1 (es)
AU (1) AU674302B2 (es)
CA (1) CA2129637C (es)
DE (1) DE69309906T2 (es)
DK (1) DK0625912T3 (es)
ES (1) ES2103468T3 (es)
GR (1) GR3024041T3 (es)
WO (1) WO1993015764A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK0670735T3 (da) 1992-11-13 1997-07-28 Univ Washington Perifisering af hæmotopoietiske stamceller.
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP2065050A1 (en) 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
KR101194176B1 (ko) 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
JP4652356B2 (ja) 2007-02-26 2011-03-16 アルプス電気株式会社 ターンシグナルスイッチ装置
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
CN109884295B (zh) * 2017-12-25 2022-03-08 苏州和锐生物科技有限公司 假单胞菌多肽、抗体捕获器件及试剂盒
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2064327T3 (es) * 1987-11-02 1995-02-01 Baylor College Medicine Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
WO1993006864A1 (en) * 1991-10-01 1993-04-15 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules

Also Published As

Publication number Publication date
CA2129637C (en) 1999-05-04
EP0625912A1 (en) 1994-11-30
DE69309906T2 (de) 1997-11-06
DK0625912T3 (da) 1997-10-27
HK1007683A1 (en) 1999-04-23
EP0625912B1 (en) 1997-04-16
GR3024041T3 (en) 1997-10-31
DE69309906D1 (de) 1997-05-22
AU3605993A (en) 1993-09-03
JP2007045843A (ja) 2007-02-22
JPH07506566A (ja) 1995-07-20
JP2004002472A (ja) 2004-01-08
WO1993015764A1 (en) 1993-08-19
ATE151642T1 (de) 1997-05-15
JP4108572B2 (ja) 2008-06-25
AU674302B2 (en) 1996-12-19
CA2129637A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
ES2103468T3 (es) Tratamiento de la inflamacion intestinal.
ATE332159T1 (de) System zum sammeln von blut ohne es zu beschädigen
ATE150319T1 (de) Behandlung von asthma
FR2633940B3 (fr) Scleroglucane traite au glyoxal et son procede d'obtention
ES2094733T3 (es) Deteccion de enfermedades o disfunciones neurologicas.
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
BR9712488A (pt) Anticorpo anti-hm 1.24 humano remodelado
HUP9802556A1 (hu) Eljárás és készítmény kötőszöveti kapcsolódások gyógyítására és helyreállítására
FR2703407B1 (fr) Dispositif et méthode de pompage comportant deux entrées d'aspiration application à un drain subhorizontal.
PT81991A (fr) Procede pour l'obtention de derives analogues de la pepstatine inhibidors de la renine et de proteases acides
ES2086521T3 (es) Proteina hibrida laci-factor x.
EP0937982A3 (de) Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
RU94020406A (ru) Способ выявления поражений эпителия желудка и применение дисахаридов для этой цели
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
WO1998051780A3 (en) Method for increasing yields or recombinant proteins
RU93015117A (ru) Способ определения "группы риска" рецидива лепры
SE8904007D0 (sv) Monoklona antikroppar och diagnostiseringsmetod
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
EP0728216A4 (en) DETECTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES BY MEANS OF AN IMPROVED METHOD OF PHOTO AFFINITY MARKING
RU96109171A (ru) Способ идентификации тела погибшего
PT88913A (pt) Processo para a preparacao da proteina pp4-x anticoagulante
RU93004826A (ru) Способ мездрения кож и шкур
ES2015239A4 (es) Esfigmomanometro.
ATE231167T1 (de) Pd-ecgf / thymidin phosphorylase spezifischer monoklonaler antikörper

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625912

Country of ref document: ES